Indian IT firm Indegene has delivered impressive financial results, with revenue from operations increasing 23.6% YoY to ₹3,511 crore in FY26. According to reports from The Financial Express, the company's Q1 FY27 performance showed even stronger momentum with revenue up 39.7% YoY to ₹1,063 crore, making it one of the fastest-growing listed IT companies in India. The growth was driven by deeper engagements with existing clients, contributions from recent acquisitions, and sustained demand for AI-enabled life sciences services. As reported by Screener.in, the momentum continues into FY27 with Q1 revenue up 39.7% YoY to ₹1,063 crore, demonstrating sustained acceleration in growth trajectory.
On August 6, Brighton Park Capital completed a significant exit from Indegene by selling its entire 8.73% stake for ₹1,105 crore through block deals. According to NSE block deal data, BPC Genesis Fund I SPV sold 1.38 crore shares (5.75% stake) for ₹727.76 crore and BPC Genesis Fund I-A SPV offloaded 71.9 lakh shares (2.98% stake) for ₹377.5 crore. The shares were sold at ₹525 per share, with nine domestic and global institutional investors acquiring the entire stake. Quant Mutual Fund emerged as the largest buyer, purchasing 95.23 lakh shares (3.95% stake) for ₹500 crore, while ICICI Prudential Mutual Fund acquired 67.67 lakh shares (2.8% stake) for ₹355.28 crore.
Unlike conventional IT service providers, Indegene operates exclusively with global pharmaceutical and medical device companies, focusing on technology-enabled commercialisation and regulatory operations. As reported by The Financial Express, the company's workforce comprises more than 27% doctors, PhDs, medical writers, and regulatory specialists working alongside software engineers. This specialized positioning allows Indegene to participate in critical projects where clients prioritise accuracy and regulatory compliance over cost, resulting in higher revenue per employee than traditional Indian IT companies. According to Screener.in, this combination makes the business difficult to replicate, as competitors must build both domain expertise and long-standing relationships with global pharmaceutical companies.
According to The Financial Express, Indegene's financial performance reflects aggressive investment for growth, with revenue per employee climbing from around $56,000 three years ago to nearly $75,000 today, significantly ahead of the $40,000-50,000 range typically generated by large Indian IT services companies. However, EBITDA margins have declined from 20.7% at the end of FY24 to 16.9% in Q1FY27, primarily due to increased investments in AI platforms and integration of acquisitions. The company recently integrated three acquisitions-BioPharm, WARN, and Cake Communications- which affected the overall profitability margins. As reported by Screener.in, the margin compression is happening due to increased investments in AI platforms and integration of acquisitions into the business, with returns on capital also moderating as recent acquisitions and investments have increased the capital base.
As reported by The Financial Express, Indegene has strengthened its position with the world's top 20 biopharmaceutical companies, with revenue from top 20 accounts increasing from ₹2,208 crore to ₹2,502 crore in FY26. The company's client base has expanded significantly, with the number of clients contributing more than $1 million in annual revenue rising from 41 to 53, and active clients generating more than $250,000 increasing from 73 in FY25 to 91 in FY26. Management estimates the outsourced life sciences operations market could nearly double from $54 billion in 2024 to around $100 billion by 2030. According to Screener.in, the increase in million-dollar relationships indicates that clients are not merely renewing contracts but expanding the scope of work, with these relationships proven to be sticky over the long term.
According to The Financial Express, Indegene has developed three AI platforms to support its growth strategy - Cortex as the core AI engine, NEXT for medical writing workflows, and Tectonic for commercial content creation. The company's Tectonic platform has already onboarded five clients within a year of launch and is expected to become a meaningful revenue contributor during FY27. As reported by Screener.in, Tectonic helps Indegene move further up the value chain into higher-value commercial content and creative strategy work, with the platform already witnessing good traction within a year of its launch. This AI strategy allows Indegene to move further up the value chain into higher-value commercial content work, positioning it well for the next phase of digital transformation in the life sciences industry.
